The Association Between Gastroesophageal Reflux Disease and Non-Small Cell Lung Cancer: A Retrospective Case-Control Study.
Gastroesophageal reflux disease
Micro-aspiration
Non-small cell lung cancer
Risk factors
Journal
Gastroenterology research
ISSN: 1918-2805
Titre abrégé: Gastroenterology Res
Pays: Canada
ID NLM: 101519422
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
11
05
2022
accepted:
27
06
2022
entrez:
21
9
2022
pubmed:
22
9
2022
medline:
22
9
2022
Statut:
ppublish
Résumé
Lung cancer is a leading cause of mortality in the USA. Non-small cell lung cancer (NSCLC) contributes to 85% of all lung cancers. It is the most prevalent subtype amongst non-smokers, and its incidence has risen in the last 20 years. In addition, gastroesophageal reflux disease (GERD) has been associated with several lung pathologies, namely idiopathic pulmonary fibrosis and asthma. We aimed to investigate the association between GERD and NSCLC by performing a retrospective, multicenter, case-control study. This is the first study of this nature to be carried out in the USA. Data were retrieved from 17 Northwell health care facilities in the New York area between the years 2010 and 2018. Inclusion criteria were patients > 18 years of age with NSCLC (large cell, adenocarcinoma, and squamous cell). They were appropriately matched with controls based on age, gender, weight, comorbidities, and medication use. Our exposure group had a diagnosis of GERD based on the International Classification of Diseases, Ninth/10th Revision (ICD 9/10) codes and endoscopic, in addition to histological evidence if present. We excluded patients with secondary lung cancers, esophageal adenocarcinoma, other primary malignancies, Barrett's esophagus, and smokers. Logistic regression was conducted to determine the adjusted odds ratio (OR) and corresponding 95% confidence interval (CI) for the association between NSCLC and GERD. A total of 1,083 subjects were included in our study: 543 (50%) patients were diagnosed with NSCLC. In this population, GERD was twice as prevalent compared to controls (20.4% vs. 11.6%, P < 0.001). Multivariate analysis demonstrated that GERD was associated with a higher risk of NSCLC compared to matched controls (OR = 1.86, 95% CI = 1.26 - 2.73). In addition, GERD patients treated with either antihistamines or proton pump inhibitors did not demonstrate an overall reduced risk of NSCLC (OR = 1.01, 95% CI = 0.48 - 2.12). Our study demonstrates that GERD is associated with a higher risk of NSCLC, irrespective of GERD treatment. We postulate that GERD patients suffer from chronic micro-aspirations leading to a prolonged inflammatory state within the lung parenchyma, triggering specific proliferative signaling pathways that may lead to malignant transformation.
Sections du résumé
Background
UNASSIGNED
Lung cancer is a leading cause of mortality in the USA. Non-small cell lung cancer (NSCLC) contributes to 85% of all lung cancers. It is the most prevalent subtype amongst non-smokers, and its incidence has risen in the last 20 years. In addition, gastroesophageal reflux disease (GERD) has been associated with several lung pathologies, namely idiopathic pulmonary fibrosis and asthma. We aimed to investigate the association between GERD and NSCLC by performing a retrospective, multicenter, case-control study. This is the first study of this nature to be carried out in the USA.
Methods
UNASSIGNED
Data were retrieved from 17 Northwell health care facilities in the New York area between the years 2010 and 2018. Inclusion criteria were patients > 18 years of age with NSCLC (large cell, adenocarcinoma, and squamous cell). They were appropriately matched with controls based on age, gender, weight, comorbidities, and medication use. Our exposure group had a diagnosis of GERD based on the International Classification of Diseases, Ninth/10th Revision (ICD 9/10) codes and endoscopic, in addition to histological evidence if present. We excluded patients with secondary lung cancers, esophageal adenocarcinoma, other primary malignancies, Barrett's esophagus, and smokers. Logistic regression was conducted to determine the adjusted odds ratio (OR) and corresponding 95% confidence interval (CI) for the association between NSCLC and GERD.
Results
UNASSIGNED
A total of 1,083 subjects were included in our study: 543 (50%) patients were diagnosed with NSCLC. In this population, GERD was twice as prevalent compared to controls (20.4% vs. 11.6%, P < 0.001). Multivariate analysis demonstrated that GERD was associated with a higher risk of NSCLC compared to matched controls (OR = 1.86, 95% CI = 1.26 - 2.73). In addition, GERD patients treated with either antihistamines or proton pump inhibitors did not demonstrate an overall reduced risk of NSCLC (OR = 1.01, 95% CI = 0.48 - 2.12).
Conclusions
UNASSIGNED
Our study demonstrates that GERD is associated with a higher risk of NSCLC, irrespective of GERD treatment. We postulate that GERD patients suffer from chronic micro-aspirations leading to a prolonged inflammatory state within the lung parenchyma, triggering specific proliferative signaling pathways that may lead to malignant transformation.
Identifiants
pubmed: 36128185
doi: 10.14740/gr1537
pmc: PMC9451582
doi:
Types de publication
Journal Article
Langues
eng
Pagination
173-179Informations de copyright
Copyright 2022, Amarnath et al.
Déclaration de conflit d'intérêts
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants, or patents received or pending, or royalties.
Références
Transl Lung Cancer Res. 2018 Aug;7(4):498-504
pubmed: 30225213
Environ Health. 2007 Feb 15;6:7
pubmed: 17302981
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Int J Cancer. 2007 Jul 1;121(1):111-8
pubmed: 17304511
J Natl Cancer Inst. 2021 Jul 08;:
pubmed: 34240195
J Fam Pract. 2021 Sep;70(7):347-349
pubmed: 34818167
PeerJ. 2016 Dec 20;4:e2753
pubmed: 28028458
Eur Arch Otorhinolaryngol. 2022 Jun;279(6):2743-2752
pubmed: 34860271
Cancer Epidemiol Biomarkers Prev. 2013 Jun;22(6):1061-8
pubmed: 23703970
Cancers (Basel). 2019 Feb 10;11(2):
pubmed: 30744199
Am J Public Health. 2008 Aug;98(8):1443-50
pubmed: 18556601
Cancer Lett. 2009 Mar 18;275(2):170-7
pubmed: 18703277
Gut. 1990 Jan;31(1):4-10
pubmed: 2318431
Gut. 2018 Feb;67(2):209-215
pubmed: 27789657
JAMA Oncol. 2021 Feb 1;7(2):302-304
pubmed: 33270100
Ann Am Thorac Soc. 2020 Apr;17(4):399-405
pubmed: 32017612